XOMA Royalty and LAVA Therapeutics amend acquisition agreement terms
PositiveFinancial Markets

XOMA Royalty and LAVA Therapeutics have successfully amended their acquisition agreement, which is a significant step forward for both companies. This adjustment reflects their commitment to collaboration and innovation in the biotech sector, potentially leading to new advancements in therapeutic solutions. The revised terms are expected to enhance operational efficiencies and drive growth, making this a noteworthy development in the industry.
— Curated by the World Pulse Now AI Editorial System